Examine Financial Forecasts Through 2012 for Products and Product Classes in the Areas of Insulin, Non-Insulin, Alternative Therapies and Diabetic Complications.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c40372) has announced the addition of "The Global Diabetes Market: Therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. , Diagnostics and Complications" to their offering. Diabetes is one of the largest therapeutic segments of global pharmaceutical sales and during the last 10 years it has grown by a compound average growth rate of nearly 20% from around US$4 billion in 1995 to over US$17 billion in 2005. Overall, anti-diabetic drugs Anti-diabetic drugs treat diabetes mellitus by lowering glucose levels in the blood. With the exceptions of insulin, exenatide, and pramlintide, all are administered orally and are thus also called oral hypoglycemic agents. sales are expected to grow dramatically over the next five years to over US$22 billion in 2012 as the addressable Reachable. When something is addressable, it can be identified and manipulated independently of its surroundings. For example, screen pixels and RAM memory are addressable. Each of the screen's picture elements can be individually turned on and off, and each of the memory's bytes can be patient population continues to increase and new, oral, injectable in·ject·a·ble adj. Capable of being injected. Used of a drug. n. A drug or medicine that can be injected. and pulmonary premium priced products enter the market to address high unmet clinical needs. The Global Diabetes Market assesses the markets for diabetes therapeutics, as well as the markets for diagnostic products and those that treat diabetic complications. This new report incorporates new clinical findings presented at the 2006 conference of the American Diabetes Association The American Diabetes Association, or the ADA, is an American health organization providing diabetes research, information and advocacy. Founded in 1940, the American Diabetes Association conducts programs in all 50 states and the District of Columbia, reaching hundreds of into our product outlooks and financial forecasts. This report also analyzes, clinically and financially, the leading products on the market, the major players, as well as the groundbreaking new products in clinical development. Financial forecasts are also provided for individual products as well as for product classes. Key Features of This Report: --A thorough global market breakdown of key products and players in the non-insulin, insulin, diagnostic and diabetic neuropathy Diabetic Neuropathy Definition Diabetic neuropathy is a nerve disorder caused by diabetes mellitus. Diabetic neuropathy may be diffuse, affecting several parts of the body, or focal, affecting a specific nerve and part of the body. areas --Individual chapters outlining the drivers of and resistors on this growing market --Clinical evaluations of products and product classes in both the insulin and non-insulin markets --Financial forecasts through 2012 for products and product classes in the areas of insulin, non-insulin, alternative therapies and diabetic complications --Thorough analysis of products in clinical development, including coverage of safety, efficacy, market potential and filing timelines --96 tables/figures illustrating scientific and market aspects of the global diabetes market Who Should Buy This Report? --Companies interested in understanding the wider opportunities and challenges in the markets for diabetes therapeutics, diagnostics and products for diabetic complications --Pharma/biotech companies wishing to identify opportunities and threats to products in these markets in order to examine a variety of profit maximization In economics, profit maximization is the process by which a firm determines the price and output level that returns the greatest profit. There are several approaches to this problem. strategies --Companies interested in understanding the state of R&D in relation to insulin, non-insulin, diagnostics and diabetic complication products About the Author: Dr. Cheryl Lee Barton graduated from Queen's University Queen's University, at Kingston, Ont., Canada; nondenominational; coeducational; founded 1841 as Queen's College. It achieved university status in 1912. It has faculties of arts and sciences, education, law, medicine, and applied science, as well as schools of in Belfast in 1993 with a doctorate from the department of Biochemistry biochemistry, science concerned chiefly with the chemistry of biological processes; it attempts to utilize the tools and concepts of chemistry, particularly organic and physical chemistry, for elucidation of the living system. and Biology. This three year project involved the characterization of novel proteins in parasites and hosts as potential targets for drug development. During this period Cheryl was offered a sabbatical sab·bat·i·cal also sab·bat·ic adj. 1. Relating to a sabbatical year. 2. Sabbatical also Sabbatic Relating or appropriate to the Sabbath as the day of rest. n. A sabbatical year. at Merck Sharp and Dohme's Neuroscience neu·ro·sci·ence n. Any of the sciences, such as neuroanatomy and neurobiology, that deal with the nervous system. neuroscience the embryology, anatomy, physiology, biochemistry and pharmacology of the nervous system. Centre in Harlow Essex to develop assays for protein identification. In 2002 Dr Barton established the consultancy Pharmavision.co.uk to provide independent, tailor made, pharmaceutical thematic research to Investment Houses, Competitive Intelligence Specialists and Pharmaceutical Companies. The research reports combine independent analysis with patient based models to forecast the potential sales growth of key drugs in clinical development. Companies Mentioned Include: - Abbott Laboratories - Amylin Pharmaceuticals Inc - Bristol-Myers Squibb - Bayer Group - Eli Lilly and Company - F. Hoffman-La Roche Ltd - GlaxoSmithKline plc - Keryx Biopharmaceuticals - LifeScan Inc - Medtronic Inc. - Merck & Co.Inc - Novartis Pharmaceuticals - Novo Nordisk A/S - Pfizer - Sanofi-Aventis - Takeda Pharmaceutical Company Ltd For more information visit http://www.researchandmarkets.com/reports/c40372 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion